AU2022385891A1 - Bacterial strains for treating disease - Google Patents

Info

Publication number

AU2022385891A1

AU2022385891A1 AU2022385891A AU2022385891A AU2022385891A1 AU 2022385891 A1 AU2022385891 A1 AU 2022385891A1 AU 2022385891 A AU2022385891 A AU 2022385891A AU 2022385891 A AU2022385891 A AU 2022385891A AU 2022385891 A1 AU2022385891 A1 AU 2022385891A1

Authority

AU

Australia

Prior art keywords

bacterial strain

colisanans

composition

cell

bacterial

Prior art date

2021-11-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 230000001580 bacterial effect Effects 0.000 title claims abstract description 408
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 74
• 201000010099 disease Diseases 0.000 title description 67
• 239000000203 mixture Substances 0.000 claims abstract description 323
• 238000000034 method Methods 0.000 claims abstract description 169
• 238000011282 treatment Methods 0.000 claims abstract description 159
• 230000002757 inflammatory effect Effects 0.000 claims abstract description 77
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 69
• 208000027866 inflammatory disease Diseases 0.000 claims abstract description 69
• 230000002265 prevention Effects 0.000 claims abstract description 43
• 241000282414 Homo sapiens Species 0.000 claims abstract description 34
• 210000004027 cell Anatomy 0.000 claims description 207
• 241000894006 Bacteria Species 0.000 claims description 121
• 241000894007 species Species 0.000 claims description 112
• 108020004465 16S ribosomal RNA Proteins 0.000 claims description 100
• 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 77
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 71
• 230000004888 barrier function Effects 0.000 claims description 69
• 208000011231 Crohn disease Diseases 0.000 claims description 49
• 206010061218 Inflammation Diseases 0.000 claims description 48
• 108090001005 Interleukin-6 Proteins 0.000 claims description 48
• 230000004054 inflammatory process Effects 0.000 claims description 47
• 230000009467 reduction Effects 0.000 claims description 46
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 41
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 41
• 239000008194 pharmaceutical composition Substances 0.000 claims description 41
• 108090000623 proteins and genes Proteins 0.000 claims description 41
• 239000000047 product Substances 0.000 claims description 36
• 230000011664 signaling Effects 0.000 claims description 36
• 102000004127 Cytokines Human genes 0.000 claims description 35
• 108090000695 Cytokines Proteins 0.000 claims description 35
• 108010065637 Interleukin-23 Proteins 0.000 claims description 34
• 102000013264 Interleukin-23 Human genes 0.000 claims description 34
• 230000004913 activation Effects 0.000 claims description 34
• 239000002207 metabolite Substances 0.000 claims description 33
• 239000006228 supernatant Substances 0.000 claims description 33
• 208000006673 asthma Diseases 0.000 claims description 30
• 239000003795 chemical substances by application Substances 0.000 claims description 29
• 239000003085 diluting agent Substances 0.000 claims description 27
• 230000035876 healing Effects 0.000 claims description 26
• 239000003814 drug Substances 0.000 claims description 24
• 230000037361 pathway Effects 0.000 claims description 22
• 208000027418 Wounds and injury Diseases 0.000 claims description 20
• 210000002919 epithelial cell Anatomy 0.000 claims description 20
• 230000006872 improvement Effects 0.000 claims description 20
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 19
• 239000003937 drug carrier Substances 0.000 claims description 17
• 210000002865 immune cell Anatomy 0.000 claims description 17
• 235000013406 prebiotics Nutrition 0.000 claims description 17
• 238000002360 preparation method Methods 0.000 claims description 16
• MBBOMCVGYCRMEA-UHFFFAOYSA-N tryptophol Chemical compound C1=CC=C2C(CCO)=CNC2=C1 MBBOMCVGYCRMEA-UHFFFAOYSA-N 0.000 claims description 16
• 239000002775 capsule Substances 0.000 claims description 15
• GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 claims description 14
• 244000005709 gut microbiome Species 0.000 claims description 14
• 238000004519 manufacturing process Methods 0.000 claims description 14
• 238000005259 measurement Methods 0.000 claims description 14
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 14
• WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 14
• 238000002560 therapeutic procedure Methods 0.000 claims description 14
• 235000013305 food Nutrition 0.000 claims description 12
• -1 TYK Proteins 0.000 claims description 11
• 102000000591 Tight Junction Proteins Human genes 0.000 claims description 11
• 108010002321 Tight Junction Proteins Proteins 0.000 claims description 11
• 230000000968 intestinal effect Effects 0.000 claims description 11
• 238000012163 sequencing technique Methods 0.000 claims description 11
• 230000009885 systemic effect Effects 0.000 claims description 11
• 206010052428 Wound Diseases 0.000 claims description 10
• 238000004113 cell culture Methods 0.000 claims description 10
• 239000002158 endotoxin Substances 0.000 claims description 10
• 229920006008 lipopolysaccharide Polymers 0.000 claims description 10
• 210000002966 serum Anatomy 0.000 claims description 10
• 201000009961 allergic asthma Diseases 0.000 claims description 9
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 9
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 9
• 230000002550 fecal effect Effects 0.000 claims description 9
• 230000002401 inhibitory effect Effects 0.000 claims description 9
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 8
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 8
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 8
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 8
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 8
• 235000015872 dietary supplement Nutrition 0.000 claims description 8
• 238000000338 in vitro Methods 0.000 claims description 8
• 239000003112 inhibitor Substances 0.000 claims description 8
• 229960003104 ornithine Drugs 0.000 claims description 8
• 238000012070 whole genome sequencing analysis Methods 0.000 claims description 8
• QZBUWPVZSXDWSB-UHFFFAOYSA-N 3-benzyl-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1N2CCCC2C(=O)NC1CC1=CC=CC=C1 QZBUWPVZSXDWSB-UHFFFAOYSA-N 0.000 claims description 7
• 206010039710 Scleroderma Diseases 0.000 claims description 7
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 7
• 206010047115 Vasculitis Diseases 0.000 claims description 7
• 108010038252 cyclo(phenylalanyl-prolyl) Proteins 0.000 claims description 7
• 208000010706 fatty liver disease Diseases 0.000 claims description 7
• 239000008187 granular material Substances 0.000 claims description 7
• 239000008188 pellet Substances 0.000 claims description 7
• 239000000843 powder Substances 0.000 claims description 7
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
• 150000003384 small molecules Chemical group 0.000 claims description 7
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 6
• 102100030703 Interleukin-22 Human genes 0.000 claims description 6
• 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims description 6
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 6
• 229960002964 adalimumab Drugs 0.000 claims description 6
• 230000000903 blocking effect Effects 0.000 claims description 6
• 239000003246 corticosteroid Substances 0.000 claims description 6
• 210000002889 endothelial cell Anatomy 0.000 claims description 6
• 230000036541 health Effects 0.000 claims description 6
• 229960000598 infliximab Drugs 0.000 claims description 6
• 108010074109 interleukin-22 Proteins 0.000 claims description 6
• 239000003826 tablet Substances 0.000 claims description 6
• XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 claims description 5
• 229960002170 azathioprine Drugs 0.000 claims description 5
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 5
• 238000005119 centrifugation Methods 0.000 claims description 5
• 229960001334 corticosteroids Drugs 0.000 claims description 5
• 239000002245 particle Substances 0.000 claims description 5
• 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 4
• 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 4
• UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 claims description 4
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 4
• 229960003459 allopurinol Drugs 0.000 claims description 4
• 238000001035 drying Methods 0.000 claims description 4
• 230000002708 enhancing effect Effects 0.000 claims description 4
• 238000004108 freeze drying Methods 0.000 claims description 4
• 239000003290 indole 3-propionic acid Substances 0.000 claims description 4
• 229940079877 pyrogallol Drugs 0.000 claims description 4
• 238000001694 spray drying Methods 0.000 claims description 4
• 230000005945 translocation Effects 0.000 claims description 4
• 238000001291 vacuum drying Methods 0.000 claims description 4
• 108090001007 Interleukin-8 Proteins 0.000 claims description 3
• 102000005741 Metalloproteases Human genes 0.000 claims description 3
• 108010006035 Metalloproteases Proteins 0.000 claims description 3
• 230000005549 barrier dysfunction Effects 0.000 claims description 3
• 230000007812 deficiency Effects 0.000 claims description 3
• 230000001939 inductive effect Effects 0.000 claims description 3
• 239000007937 lozenge Substances 0.000 claims description 3
• 239000002773 nucleotide Substances 0.000 claims description 3
• 125000003729 nucleotide group Chemical group 0.000 claims description 3
• 230000001839 systemic circulation Effects 0.000 claims description 3
• 241000193403 Clostridium Species 0.000 claims description 2
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
• 206010022714 Intestinal ulcer Diseases 0.000 claims description 2
• 108010063045 Lactoferrin Proteins 0.000 claims description 2
• 102000013519 Lipocalin-2 Human genes 0.000 claims description 2
• 108010051335 Lipocalin-2 Proteins 0.000 claims description 2
• 230000010393 epithelial cell migration Effects 0.000 claims description 2
• 230000008556 epithelial cell proliferation Effects 0.000 claims description 2
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
• 229940078795 lactoferrin Drugs 0.000 claims description 2
• 235000021242 lactoferrin Nutrition 0.000 claims description 2
• 239000006187 pill Substances 0.000 claims description 2
• 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 10
• 229960004308 acetylcysteine Drugs 0.000 claims 2
• 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims 1
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
• 102000010445 Lactoferrin Human genes 0.000 claims 1
• 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 100
• 230000001225 therapeutic effect Effects 0.000 abstract description 30
• 230000006806 disease prevention Effects 0.000 abstract description 2
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 67
• 230000001404 mediated effect Effects 0.000 description 60
• 230000000694 effects Effects 0.000 description 54
• 239000002609 medium Substances 0.000 description 51
• 102000004889 Interleukin-6 Human genes 0.000 description 47
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 44
• 229920003045 dextran sodium sulfate Polymers 0.000 description 43
• 241000699670 Mus sp. Species 0.000 description 42
• 239000000284 extract Substances 0.000 description 37
• 239000003981 vehicle Substances 0.000 description 35
• 206010009887 colitis Diseases 0.000 description 32
• 239000012228 culture supernatant Substances 0.000 description 32
• 102000044820 Zonula Occludens-1 Human genes 0.000 description 28
• 108700007340 Zonula Occludens-1 Proteins 0.000 description 28
• 102000013691 Interleukin-17 Human genes 0.000 description 27
• 108050003558 Interleukin-17 Proteins 0.000 description 27
• 241001465754 Metazoa Species 0.000 description 26
• 210000001072 colon Anatomy 0.000 description 26
• 238000012360 testing method Methods 0.000 description 26
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 25
• 238000004458 analytical method Methods 0.000 description 23
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
• 238000009472 formulation Methods 0.000 description 21
• 210000000936 intestine Anatomy 0.000 description 21
• 230000006378 damage Effects 0.000 description 20
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 19
• 239000000243 solution Substances 0.000 description 19
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
• 210000000349 chromosome Anatomy 0.000 description 17
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 17
• 229960004618 prednisone Drugs 0.000 description 17
• 208000025865 Ulcer Diseases 0.000 description 16
• 230000001668 ameliorated effect Effects 0.000 description 16
• 238000003556 assay Methods 0.000 description 16
• 238000002474 experimental method Methods 0.000 description 16
• 239000003550 marker Substances 0.000 description 16
• 208000024891 symptom Diseases 0.000 description 16
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
• 239000000090 biomarker Substances 0.000 description 15
• 150000001875 compounds Chemical class 0.000 description 15
• 229940079593 drug Drugs 0.000 description 15
• 235000011187 glycerol Nutrition 0.000 description 15
• 238000001543 one-way ANOVA Methods 0.000 description 15
• 102000004169 proteins and genes Human genes 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 241000123753 Ruminococcus bromii Species 0.000 description 14
• 235000018102 proteins Nutrition 0.000 description 14
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
• 238000012937 correction Methods 0.000 description 13
• 239000001301 oxygen Substances 0.000 description 13
• 229910052760 oxygen Inorganic materials 0.000 description 13
• 239000000523 sample Substances 0.000 description 13
• 230000019491 signal transduction Effects 0.000 description 13
• 229920002558 Curdlan Polymers 0.000 description 12
• 239000001879 Curdlan Substances 0.000 description 12
• 229930105110 Cyclosporin A Natural products 0.000 description 12
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 12
• 108010036949 Cyclosporine Proteins 0.000 description 12
• 102000003814 Interleukin-10 Human genes 0.000 description 12
• 108090000174 Interleukin-10 Proteins 0.000 description 12
• 210000004369 blood Anatomy 0.000 description 12
• 239000008280 blood Substances 0.000 description 12
• 235000019316 curdlan Nutrition 0.000 description 12
• 229940078035 curdlan Drugs 0.000 description 12
• 230000012010 growth Effects 0.000 description 12
• 239000000463 material Substances 0.000 description 12
• 239000006041 probiotic Substances 0.000 description 12
• 235000018291 probiotics Nutrition 0.000 description 12
• 230000036269 ulceration Effects 0.000 description 12
• 238000011870 unpaired t-test Methods 0.000 description 12
• 230000005526 G1 to G0 transition Effects 0.000 description 11
• 206010003246 arthritis Diseases 0.000 description 11
• 230000008901 benefit Effects 0.000 description 11
• 230000003870 intestinal permeability Effects 0.000 description 11
• 239000010410 layer Substances 0.000 description 11
• 230000036961 partial effect Effects 0.000 description 11
• 235000002639 sodium chloride Nutrition 0.000 description 11
• 239000007921 spray Substances 0.000 description 11
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
• 208000014674 injury Diseases 0.000 description 10
• 235000013336 milk Nutrition 0.000 description 10
• 239000008267 milk Substances 0.000 description 10
• 210000004080 milk Anatomy 0.000 description 10
• 235000000346 sugar Nutrition 0.000 description 10
• 210000001578 tight junction Anatomy 0.000 description 10
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
• 201000004681 Psoriasis Diseases 0.000 description 9
• 229920002472 Starch Polymers 0.000 description 9
• 230000002496 gastric effect Effects 0.000 description 9
• 230000028709 inflammatory response Effects 0.000 description 9
• 230000005012 migration Effects 0.000 description 9
• 238000013508 migration Methods 0.000 description 9
• 238000010172 mouse model Methods 0.000 description 9
• 230000035699 permeability Effects 0.000 description 9
• 239000013641 positive control Substances 0.000 description 9
• 230000000529 probiotic effect Effects 0.000 description 9
• 239000008107 starch Substances 0.000 description 9
• 235000019698 starch Nutrition 0.000 description 9
• 229920001817 Agar Polymers 0.000 description 8
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 8
• 239000004012 Tofacitinib Substances 0.000 description 8
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 8
• 239000013543 active substance Substances 0.000 description 8
• 239000008272 agar Substances 0.000 description 8
• 238000013459 approach Methods 0.000 description 8
• 230000037396 body weight Effects 0.000 description 8
• 229910052799 carbon Inorganic materials 0.000 description 8
• 235000011089 carbon dioxide Nutrition 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 208000009326 ileitis Diseases 0.000 description 8
• 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• 239000012528 membrane Substances 0.000 description 8
• 244000005700 microbiome Species 0.000 description 8
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 8
• 229960004023 minocycline Drugs 0.000 description 8
• 230000008506 pathogenesis Effects 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 150000003839 salts Chemical class 0.000 description 8
• 239000007901 soft capsule Substances 0.000 description 8
• 230000000638 stimulation Effects 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 229960001350 tofacitinib Drugs 0.000 description 8
• UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• PLVPPLCLBIEYEA-AATRIKPKSA-N (E)-3-(indol-3-yl)acrylic acid Chemical compound C1=CC=C2C(/C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-AATRIKPKSA-N 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
• PLVPPLCLBIEYEA-WAYWQWQTSA-N Indole-3-acrylic acid Natural products C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 7
• 230000009266 disease activity Effects 0.000 description 7
• 238000010828 elution Methods 0.000 description 7
• 230000003628 erosive effect Effects 0.000 description 7
• 239000008103 glucose Substances 0.000 description 7
• 235000001727 glucose Nutrition 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 229960001375 lactose Drugs 0.000 description 7
• 239000008101 lactose Substances 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 210000004379 membrane Anatomy 0.000 description 7
• 230000002503 metabolic effect Effects 0.000 description 7
• 238000011201 multiple comparisons test Methods 0.000 description 7
• 150000007523 nucleic acids Chemical class 0.000 description 7
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
• 229920005989 resin Polymers 0.000 description 7
• 239000011347 resin Substances 0.000 description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
• 102000019034 Chemokines Human genes 0.000 description 6
• 108010012236 Chemokines Proteins 0.000 description 6
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
• 208000003456 Juvenile Arthritis Diseases 0.000 description 6
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 6
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 6
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 6
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 238000000540 analysis of variance Methods 0.000 description 6
• 230000009286 beneficial effect Effects 0.000 description 6
• 150000001720 carbohydrates Chemical class 0.000 description 6
• 235000014633 carbohydrates Nutrition 0.000 description 6
• 230000012292 cell migration Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 6
• 210000003097 mucus Anatomy 0.000 description 6
• 201000008482 osteoarthritis Diseases 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 239000003755 preservative agent Substances 0.000 description 6
• 238000002203 pretreatment Methods 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 230000002792 vascular Effects 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
• 208000017667 Chronic Disease Diseases 0.000 description 5
• 238000001061 Dunnett's test Methods 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 5
• 241000192125 Firmicutes Species 0.000 description 5
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
• 208000032843 Hemorrhage Diseases 0.000 description 5
• 108010024121 Janus Kinases Proteins 0.000 description 5
• 102000015617 Janus Kinases Human genes 0.000 description 5
• 238000012313 Kruskal-Wallis test Methods 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 241001529936 Murinae Species 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• 108010010057 TYK2 Kinase Proteins 0.000 description 5
• 239000008186 active pharmaceutical agent Substances 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 230000003110 anti-inflammatory effect Effects 0.000 description 5
• 230000000740 bleeding effect Effects 0.000 description 5
• 229920001429 chelating resin Polymers 0.000 description 5
• 208000037976 chronic inflammation Diseases 0.000 description 5
• 230000001332 colony forming effect Effects 0.000 description 5
• 238000012258 culturing Methods 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 229940088679 drug related substance Drugs 0.000 description 5
• 230000008482 dysregulation Effects 0.000 description 5
• 238000009505 enteric coating Methods 0.000 description 5
• 239000002702 enteric coating Substances 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 210000003405 ileum Anatomy 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 102000039446 nucleic acids Human genes 0.000 description 5
• 108020004707 nucleic acids Proteins 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 238000011218 seed culture Methods 0.000 description 5
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 5
• 239000004299 sodium benzoate Substances 0.000 description 5
• 235000010234 sodium benzoate Nutrition 0.000 description 5
• 238000010186 staining Methods 0.000 description 5
• 229960004793 sucrose Drugs 0.000 description 5
• 238000004885 tandem mass spectrometry Methods 0.000 description 5
• 239000007160 ty medium Substances 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• 239000011782 vitamin Substances 0.000 description 5
• 235000013343 vitamin Nutrition 0.000 description 5
• 229940088594 vitamin Drugs 0.000 description 5
• 229930003231 vitamin Natural products 0.000 description 5
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
• 208000023373 Crohn ileitis Diseases 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 241000605980 Faecalibacterium prausnitzii Species 0.000 description 4
• 241000962919 Faecalibacterium prausnitzii A2-165 Species 0.000 description 4
• 102100033105 Interleukin-17C Human genes 0.000 description 4
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
• 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 4
• 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 241000288906 Primates Species 0.000 description 4
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
• 239000005862 Whey Substances 0.000 description 4
• 102000007544 Whey Proteins Human genes 0.000 description 4
• 108010046377 Whey Proteins Proteins 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 229940024606 amino acid Drugs 0.000 description 4
• 235000001014 amino acid Nutrition 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 230000015556 catabolic process Effects 0.000 description 4
• 239000013592 cell lysate Substances 0.000 description 4
• 238000002052 colonoscopy Methods 0.000 description 4
• 229960002433 cysteine Drugs 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 239000003651 drinking water Substances 0.000 description 4
• 235000020188 drinking water Nutrition 0.000 description 4
• 238000005538 encapsulation Methods 0.000 description 4
• 238000001839 endoscopy Methods 0.000 description 4
• 210000003608 fece Anatomy 0.000 description 4
• 238000000855 fermentation Methods 0.000 description 4
• 230000004151 fermentation Effects 0.000 description 4
• 210000002175 goblet cell Anatomy 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 230000002519 immonomodulatory effect Effects 0.000 description 4
• 230000001771 impaired effect Effects 0.000 description 4
• 230000008595 infiltration Effects 0.000 description 4
• 238000001764 infiltration Methods 0.000 description 4
• 108010074108 interleukin-21 Proteins 0.000 description 4
• 210000005026 intestinal epithelial barrier Anatomy 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 210000002429 large intestine Anatomy 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 238000010232 migration assay Methods 0.000 description 4
• 210000004400 mucous membrane Anatomy 0.000 description 4
• 238000003305 oral gavage Methods 0.000 description 4
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 230000002335 preservative effect Effects 0.000 description 4
• 230000000770 proinflammatory effect Effects 0.000 description 4
• 230000008929 regeneration Effects 0.000 description 4
• 238000011069 regeneration method Methods 0.000 description 4
• 239000012266 salt solution Substances 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 231100000397 ulcer Toxicity 0.000 description 4
• 150000003722 vitamin derivatives Chemical class 0.000 description 4
• 208000016261 weight loss Diseases 0.000 description 4
• 230000004580 weight loss Effects 0.000 description 4
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 3
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
• 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 3
• 206010003497 Asphyxia Diseases 0.000 description 3
• 108010074051 C-Reactive Protein Proteins 0.000 description 3
• 102100032752 C-reactive protein Human genes 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 208000014997 Crohn colitis Diseases 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
• 206010015150 Erythema Diseases 0.000 description 3
• 241000282326 Felis catus Species 0.000 description 3
• 239000001828 Gelatine Substances 0.000 description 3
• 102100025255 Haptoglobin Human genes 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 229920001202 Inulin Polymers 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 239000005089 Luciferase Substances 0.000 description 3
• 241000736262 Microbiota Species 0.000 description 3
• 102000015728 Mucins Human genes 0.000 description 3
• 108010063954 Mucins Proteins 0.000 description 3
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 239000004376 Sucralose Substances 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 239000002870 angiogenesis inducing agent Substances 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 230000002238 attenuated effect Effects 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 230000000975 bioactive effect Effects 0.000 description 3
• 230000008033 biological extinction Effects 0.000 description 3
• 238000001574 biopsy Methods 0.000 description 3
• 238000012754 cardiac puncture Methods 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000005754 cellular signaling Effects 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 235000010980 cellulose Nutrition 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
• 230000001609 comparable effect Effects 0.000 description 3
• 238000004624 confocal microscopy Methods 0.000 description 3
• 229960001305 cysteine hydrochloride Drugs 0.000 description 3
• 108010057085 cytokine receptors Proteins 0.000 description 3
• 102000003675 cytokine receptors Human genes 0.000 description 3
• 239000008367 deionised water Substances 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 238000007865 diluting Methods 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
• 231100000321 erythema Toxicity 0.000 description 3
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 150000004676 glycans Chemical class 0.000 description 3
• 208000024908 graft versus host disease Diseases 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
• 229940029339 inulin Drugs 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 229940096504 methionine 200 mg Drugs 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• 235000010981 methylcellulose Nutrition 0.000 description 3
• 239000001923 methylcellulose Substances 0.000 description 3
• 230000000813 microbial effect Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 210000004877 mucosa Anatomy 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 229920001282 polysaccharide Polymers 0.000 description 3
• 239000005017 polysaccharide Substances 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 210000000664 rectum Anatomy 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 235000017557 sodium bicarbonate Nutrition 0.000 description 3
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000004334 sorbic acid Substances 0.000 description 3
• 235000010199 sorbic acid Nutrition 0.000 description 3
• 229940075582 sorbic acid Drugs 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
• 235000019408 sucralose Nutrition 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 230000000451 tissue damage Effects 0.000 description 3
• 231100000827 tissue damage Toxicity 0.000 description 3
• 230000001960 triggered effect Effects 0.000 description 3
• 238000007492 two-way ANOVA Methods 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• 108010027843 zonulin Proteins 0.000 description 3
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 241000605059 Bacteroidetes Species 0.000 description 2
• 241000186000 Bifidobacterium Species 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
• 229930091371 Fructose Natural products 0.000 description 2
• 239000005715 Fructose Substances 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 238000003794 Gram staining Methods 0.000 description 2
• 206010018691 Granuloma Diseases 0.000 description 2
• 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 2
• 102100033096 Interleukin-17D Human genes 0.000 description 2
• 102100036672 Interleukin-23 receptor Human genes 0.000 description 2
• 108010066979 Interleukin-27 Proteins 0.000 description 2
• 102000042838 JAK family Human genes 0.000 description 2
• 108091082332 JAK family Proteins 0.000 description 2
• 102000014748 Junctional Adhesion Molecules Human genes 0.000 description 2
• 108010064064 Junctional Adhesion Molecules Proteins 0.000 description 2
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
• 241000254158 Lampyridae Species 0.000 description 2
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
• 238000007476 Maximum Likelihood Methods 0.000 description 2
• 206010028116 Mucosal inflammation Diseases 0.000 description 2
• 206010028124 Mucosal ulceration Diseases 0.000 description 2
• MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
• 208000007101 Muscle Cramp Diseases 0.000 description 2
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 238000001430 Omnibus test Methods 0.000 description 2
• 108010013639 Peptidoglycan Proteins 0.000 description 2
• DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 206010039705 Scleritis Diseases 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• 102000012736 Zonula Occludens Proteins Human genes 0.000 description 2
• 108010079485 Zonula Occludens Proteins Proteins 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 206010000269 abscess Diseases 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
• WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 229960004977 anhydrous lactose Drugs 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 210000000436 anus Anatomy 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000003816 axenic effect Effects 0.000 description 2
• 210000004082 barrier epithelial cell Anatomy 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 238000004820 blood count Methods 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 229940105329 carboxymethylcellulose Drugs 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 239000013553 cell monolayer Substances 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 229960002173 citrulline Drugs 0.000 description 2
• 235000013477 citrulline Nutrition 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 230000000112 colonic effect Effects 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 230000000052 comparative effect Effects 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 235000005822 corn Nutrition 0.000 description 2
• 238000003235 crystal violet staining Methods 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 229910021641 deionized water Inorganic materials 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 235000013681 dietary sucrose Nutrition 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000007140 dysbiosis Effects 0.000 description 2
• 238000000132 electrospray ionisation Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 230000004890 epithelial barrier function Effects 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 108091022862 fatty acid binding Proteins 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 239000010408 film Substances 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 235000013350 formula milk Nutrition 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 229960001743 golimumab Drugs 0.000 description 2
• 230000033687 granuloma formation Effects 0.000 description 2
• 230000007407 health benefit Effects 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 230000004957 immunoregulator effect Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 210000005027 intestinal barrier Anatomy 0.000 description 2
• 230000007358 intestinal barrier function Effects 0.000 description 2
• 230000003871 intestinal function Effects 0.000 description 2
• BSABBBMNWQWLLU-UHFFFAOYSA-N lactaldehyde Chemical compound CC(O)C=O BSABBBMNWQWLLU-UHFFFAOYSA-N 0.000 description 2
• JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
• 229960000511 lactulose Drugs 0.000 description 2
• PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 229960001855 mannitol Drugs 0.000 description 2
• 210000003622 mature neutrocyte Anatomy 0.000 description 2
• 229960004963 mesalazine Drugs 0.000 description 2
• 230000037353 metabolic pathway Effects 0.000 description 2
• 238000002705 metabolomic analysis Methods 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 150000002772 monosaccharides Chemical class 0.000 description 2
• 208000008795 neuromyelitis optica Diseases 0.000 description 2
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
• BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 235000016709 nutrition Nutrition 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 229920001542 oligosaccharide Polymers 0.000 description 2
• 150000002482 oligosaccharides Chemical class 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 239000001814 pectin Substances 0.000 description 2
• 229920001277 pectin Polymers 0.000 description 2
• 235000010987 pectin Nutrition 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 239000004417 polycarbonate Substances 0.000 description 2
• 229920000515 polycarbonate Polymers 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 108020004418 ribosomal RNA Proteins 0.000 description 2
• 238000004062 sedimentation Methods 0.000 description 2
• 235000021391 short chain fatty acids Nutrition 0.000 description 2
• 150000004666 short chain fatty acids Chemical class 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 235000010413 sodium alginate Nutrition 0.000 description 2
• 239000000661 sodium alginate Substances 0.000 description 2
• 229940005550 sodium alginate Drugs 0.000 description 2
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
• 235000021262 sour milk Nutrition 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 238000009987 spinning Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000013595 supernatant sample Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 230000008719 thickening Effects 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
• 229960004914 vedolizumab Drugs 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 235000008939 whole milk Nutrition 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 241001015283 Acutalibacter Species 0.000 description 1
• 239000012099 Alexa Fluor family Substances 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
• 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
• 241000282672 Ateles sp. Species 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 235000007319 Avena orientalis Nutrition 0.000 description 1
• 244000075850 Avena orientalis Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 208000034309 Bacterial disease carrier Diseases 0.000 description 1
• 206010070545 Bacterial translocation Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
• 229920002498 Beta-glucan Polymers 0.000 description 1
• 241001608472 Bifidobacterium longum Species 0.000 description 1
• 239000002028 Biomass Substances 0.000 description 1
• 241000157302 Bison bison athabascae Species 0.000 description 1
• 208000031648 Body Weight Changes Diseases 0.000 description 1
• 206010051728 Bone erosion Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282461 Canis lupus Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 206010007710 Cartilage injury Diseases 0.000 description 1
• 240000008886 Ceratonia siliqua Species 0.000 description 1
• 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
• 241000282994 Cervidae Species 0.000 description 1
• 102000006303 Chaperonin 60 Human genes 0.000 description 1
• 108010058432 Chaperonin 60 Proteins 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 241000207199 Citrus Species 0.000 description 1
• 102000002029 Claudin Human genes 0.000 description 1
• 108050009302 Claudin Proteins 0.000 description 1
• 241001112696 Clostridia Species 0.000 description 1
• 206010009691 Clubbing Diseases 0.000 description 1
• 241001478240 Coccus Species 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 230000007023 DNA restriction-modification system Effects 0.000 description 1
• 206010051055 Deep vein thrombosis Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 241000271571 Dromaius novaehollandiae Species 0.000 description 1
• 208000027244 Dysbiosis Diseases 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 206010015084 Episcleritis Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 206010015226 Erythema nodosum Diseases 0.000 description 1
• 108050008832 Fatty acid-binding protein, intestinal Proteins 0.000 description 1
• 102100026748 Fatty acid-binding protein, intestinal Human genes 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• 238000000729 Fisher's exact test Methods 0.000 description 1
• 241001453172 Fusobacteria Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 229920001503 Glucan Polymers 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 229920002488 Hemicellulose Polymers 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
• 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 description 1
• 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
• 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
• 102000039989 IL-17 family Human genes 0.000 description 1
• 108091069193 IL-17 family Proteins 0.000 description 1
• 208000020060 Increased inflammatory response Diseases 0.000 description 1
• 102100033461 Interleukin-17A Human genes 0.000 description 1
• 102100033454 Interleukin-17F Human genes 0.000 description 1
• 101710195550 Interleukin-23 receptor Proteins 0.000 description 1
• 102100036679 Interleukin-26 Human genes 0.000 description 1
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000000585 Interleukin-9 Human genes 0.000 description 1
• 206010022699 Intestinal stenosis Diseases 0.000 description 1
• 102000006391 Ion Pumps Human genes 0.000 description 1
• 108010083687 Ion Pumps Proteins 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 230000035986 JAK-STAT signaling Effects 0.000 description 1
• 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
• 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
• 239000004201 L-cysteine Substances 0.000 description 1
• 235000013878 L-cysteine Nutrition 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 241000186660 Lactobacillus Species 0.000 description 1
• 102100032241 Lactotransferrin Human genes 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 241000408529 Libra Species 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000049280 MARVEL Domain Containing 2 Human genes 0.000 description 1
• 108050009393 MARVEL domain-containing protein 2 Proteins 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 241000208467 Macadamia Species 0.000 description 1
• 241000283923 Marmota monax Species 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• 206010061297 Mucosal erosion Diseases 0.000 description 1
• 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 241000282339 Mustela Species 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 102000003940 Occludin Human genes 0.000 description 1
• 108090000304 Occludin Proteins 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 229940123973 Oxygen scavenger Drugs 0.000 description 1
• 238000010222 PCR analysis Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 241000425347 Phyla <beetle> Species 0.000 description 1
• 229920001100 Polydextrose Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 241000192142 Proteobacteria Species 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 238000003559 RNA-seq method Methods 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038063 Rectal haemorrhage Diseases 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 229920000294 Resistant starch Polymers 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 108020001027 Ribosomal DNA Proteins 0.000 description 1
• CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
• 241000190045 Ruthenibacterium lactatiformans Species 0.000 description 1
• 241000277331 Salmonidae Species 0.000 description 1
• 101710184528 Scaffolding protein Proteins 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 241000272534 Struthio camelus Species 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 240000006474 Theobroma bicolor Species 0.000 description 1
• 240000003243 Thuja occidentalis Species 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 238000010162 Tukey test Methods 0.000 description 1
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
• 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 241001261005 Verrucomicrobia Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 241000282485 Vulpes vulpes Species 0.000 description 1
• 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
• 241001246487 [Clostridium] bolteae Species 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 210000002867 adherens junction Anatomy 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 235000020194 almond milk Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 230000004099 anaerobic respiration Effects 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 230000037358 bacterial metabolism Effects 0.000 description 1
• 230000007375 bacterial translocation Effects 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 229940009291 bifidobacterium longum Drugs 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 230000003851 biochemical process Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 229940126587 biotherapeutics Drugs 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 238000007664 blowing Methods 0.000 description 1
• 230000004579 body weight change Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 235000015155 buttermilk Nutrition 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
• 241001233037 catfish Species 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000003570 cell viability assay Methods 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 229960003115 certolizumab pegol Drugs 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 235000015111 chews Nutrition 0.000 description 1
• 201000001883 cholelithiasis Diseases 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 235000020971 citrus fruits Nutrition 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 235000020197 coconut milk Nutrition 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 235000020186 condensed milk Nutrition 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 235000020247 cow milk Nutrition 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 235000015140 cultured milk Nutrition 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229910003460 diamond Inorganic materials 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 208000014793 distal colitis Diseases 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 229940096118 ella Drugs 0.000 description 1
• 239000002662 enteric coated tablet Substances 0.000 description 1
• 208000020947 enthesitis Diseases 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 230000008378 epithelial damage Effects 0.000 description 1
• 230000009786 epithelial differentiation Effects 0.000 description 1
• 230000009841 epithelial lesion Effects 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 229950004912 etrolizumab Drugs 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 235000021001 fermented dairy product Nutrition 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• 235000019688 fish Nutrition 0.000 description 1
• 206010016766 flatulence Diseases 0.000 description 1
• 235000019541 flavored milk drink Nutrition 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000009541 flexible sigmoidoscopy Methods 0.000 description 1
• 238000005189 flocculation Methods 0.000 description 1
• 230000016615 flocculation Effects 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 239000012909 foetal bovine serum Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 208000001130 gallstones Diseases 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000002575 gastroscopy Methods 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 239000007897 gelcap Substances 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 235000020251 goat milk Nutrition 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 230000009643 growth defect Effects 0.000 description 1
• 230000007773 growth pattern Effects 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 229940116364 hard fat Drugs 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 229940097789 heavy mineral oil Drugs 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 230000036732 histological change Effects 0.000 description 1
• 230000009215 host defense mechanism Effects 0.000 description 1
• 102000057111 human IL23R Human genes 0.000 description 1
• 102000052611 human IL6 Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 235000015243 ice cream Nutrition 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003125 immunofluorescent labeling Methods 0.000 description 1
• 230000002998 immunogenetic effect Effects 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• IVYPNXXAYMYVSP-UHFFFAOYSA-N indole-3-methanol Chemical compound C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229940039696 lactobacillus Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000012978 lignocellulosic material Substances 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 238000010859 live-cell imaging Methods 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 239000000845 maltitol Substances 0.000 description 1
• 235000010449 maltitol Nutrition 0.000 description 1
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
• 229940035436 maltitol Drugs 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000006680 metabolic alteration Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000012982 microporous membrane Substances 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 235000020124 milk-based beverage Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 229940051875 mucins Drugs 0.000 description 1
• 230000003232 mucoadhesive effect Effects 0.000 description 1
• 230000008937 mucosal improvement Effects 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 238000002663 nebulization Methods 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 238000007481 next generation sequencing Methods 0.000 description 1
• 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
• 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
• 239000002417 nutraceutical Substances 0.000 description 1
• 235000021436 nutraceutical agent Nutrition 0.000 description 1
• 235000020262 oat milk Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000007918 pathogenicity Effects 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000029553 photosynthesis Effects 0.000 description 1
• 238000010672 photosynthesis Methods 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 235000020245 plant milk Nutrition 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 235000013856 polydextrose Nutrition 0.000 description 1
• 239000001259 polydextrose Substances 0.000 description 1
• 229940035035 polydextrose Drugs 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 108010055896 polyornithine Proteins 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000036544 posture Effects 0.000 description 1
• 230000003334 potential effect Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 235000008476 powdered milk Nutrition 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000013630 prepared media Substances 0.000 description 1
• 230000002046 pro-migratory effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 239000007671 pyg medium Substances 0.000 description 1
• 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 230000003014 reinforcing effect Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000000754 repressing effect Effects 0.000 description 1
• 235000021254 resistant starch Nutrition 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000011268 retreatment Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000005096 rolling process Methods 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 235000020254 sheep milk Nutrition 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 229960003885 sodium benzoate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 235000013322 soy milk Nutrition 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 239000012128 staining reagent Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 230000004152 substrate-level phosphorylation Effects 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 210000004876 tela submucosa Anatomy 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 239000010409 thin film Substances 0.000 description 1
• 210000000779 thoracic wall Anatomy 0.000 description 1
• 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000007723 transport mechanism Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 108091052247 type I cytokine receptor family Proteins 0.000 description 1
• 102000042286 type I cytokine receptor family Human genes 0.000 description 1
• 102000042287 type II cytokine receptor family Human genes 0.000 description 1
• 108091052254 type II cytokine receptor family Proteins 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
• 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
• 229910021642 ultra pure water Inorganic materials 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
• 239000012498 ultrapure water Substances 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229960003824 ustekinumab Drugs 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 229940054967 vanquish Drugs 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 235000013618 yogurt Nutrition 0.000 description 1
• 229930195724 β-lactose Natural products 0.000 description 1